Trump Administration Unveils 2026 National Drug Control Strategy Focused on Dismantling FTOs and TCOs

The Trump administration has published its 2026 National Drug Control Strategy, a plan that lays out tangible, measurable goals for disrupting the global supply of illicit drugs by targeting the foreign terrorist organizations and transnational criminal organizations the administration blames for fueling drug deaths in the United States. Released on May 4, 2026, by the Office of National Drug Control Policy under Director Sara Carter — the official often referred to as the "drug czar" — the document is now issued biennially and frames itself as the administration's most ambitious counterdrug plan to date. Carter described it as a roadmap to dismantling and financially ruining the cartels and trafficking networks that, in the administration's telling, have operated with impunity across the Western Hemisphere for decades.The Strategy arrives against a backdrop the administration treats as a national-security emergency rather than solely a public-health one. The document traces a crisis that escalated from prescription opioids to heroin and then to illicitly manufactured fentanyl, which pushed annual U.S. overdose deaths above 100,000 for three consecutive years from 2021 to 2023, peaking at nearly 108,000 in 2022. It notes that provisional data show a substantial decline since then — to roughly 72,800 deaths for the 12 months ending in August 2025 — but argues that the toll still vastly exceeds anything seen before fentanyl became widely available, and so continues to constitute a clear threat to the American people. That framing is reinforced by an executive order cited in the document that formally designates fentanyl as a Weapon of Mass Destruction, directing the government to treat it with a posture commensurate with chemical, biological, and radiological dangers. The supply-side, FTO-focused emphasis also follows the administration's earlier move to designate a series of cartels and transnational gangs as foreign terrorist organizations, a designation that underpins much of the enforcement architecture the Strategy relies upon.The Strategy organizes its goals into several concrete lines of effort. First, to secure global supply chains it seeks to increase participation in the Customs Trade Partnership Against Terrorism (CTPAT), a voluntary public-private program that encourages companies to adopt enhanced security measures and receive prioritized processing at U.S. ports. The administration set participation targets of 445 companies by 2026 and 471 by 2029, up from 428 in 2024. It also aims to grow the number of companies in foreign Authorized Economic Operator (AEO) programs with Mutual Recognition Agreements with U.S. Customs and Border Protection (CBP) from 23,142 in 2024 to targeted totals of 24,068 by 2026 and 25,465 by 2029. The logic is to make the legitimate shipping channels that cartels exploit harder to penetrate, by rewarding verified, security-compliant traders and tightening scrutiny elsewhere.Second, to reduce drug flows into the United States the Strategy establishes measurable seizure and incident-reporting goals. It seeks increased reporting of precursor and related chemical seizures through the Precursor Incident Communication System (PICS) by China, Colombia, India, and Mexico — raising combined reported incidents from 11 in 2024 to targets of 48 in 2026 and 208 in 2029. The plan also calls for larger Coast Guard cocaine seizures destined for the U.S., setting a goal of 210 metric tons in 2026, up from 106.3 metric tons in 2024. For Customs and Border Protection, the Strategy targets 887,844 pounds of illicit drugs seized at and between ports of entry in 2026, an increase from 807,131 pounds in 2024. These interdiction targets sit alongside broader commitments in the plan to expand detection technology, formalize joint operations through newly established Homeland Security Task Forces, and draw on Department of War support to reinforce border security — reflecting the administration's stated intent to treat trafficking as a militarized as well as a law-enforcement problem.Domestically, the Strategy aims to degrade criminal logistics by increasing the number of drug trafficking organizations (DTOs) and money laundering organizations (MLOs) disrupted or dismantled by High Intensity Drug Trafficking Area (HIDTA) task forces. After fluctuations in recent years, the plan targets 3,337 such organizations in 2026 and 3,530 in 2029. It also seeks to expand regulatory enforcement by increasing the number of Food and Drug Administration (FDA) Warning Letters issued to companies selling unauthorized opioid products, with goals of 13 letters in 2026 and 18 in 2029.The document further outlines a global campaign to coordinate law enforcement and intelligence efforts against designated TCOs. New metrics include response-rate targets for intelligence community requests (90 percent in 2026 and 95 percent in 2029) and increases in arrests of individuals on the Consolidated Priority Organization Target (CPOT) List, with targets of nine arrests in 2026 and twelve in 2029. The Strategy also sets numerical goals for recovering firearms destined for TCOs and FTOs and for imposing sanctions under Executive Order 14059, with targeted new sanctions of 148 persons in 2026 and 156 in 2029. The emphasis throughout this pillar is on striking at cartel leadership and finances rather than merely intercepting shipments at the border — resourcing enterprise-level investigations, targeting online drug marketplaces, and directing financial sanctions at the money launderers who sustain trafficking operations.While the supply-side and enforcement metrics dominate the Strategy's measurable targets, the plan also encompasses a demand-reduction agenda that the administration presents as the necessary complement to its offensive abroad. It calls for investment in primary prevention aimed especially at young people, new partnerships with youth-serving organizations, and a national media and education campaign promoting a drug-free life as a social norm, alongside an expanded federal drug-free workplace program. On the response side, it seeks wider availability of naloxone and the development of new overdose-reversal medications, updated rescue training, and a standardized approach to responding to and reporting mass-overdose clusters. The Strategy further leans on faith-based organizations for prevention and recovery, and proposes modernizing the nation's drug-threat surveillance through advanced data systems, artificial intelligence, and national wastewater testing — an attempt to build what it describes as a more proactive, agile system for identifying emerging threats before they take hold.Taken together, the administration frames the Strategy as a multi-agency, "whole-of-government" effort intended to revive an offensive posture in the war on drugs by combining international diplomatic pressure, supply-chain security measures, and stepped-up domestic enforcement. The approach emphasizes measurable benchmarks and cooperation with partner countries and private-sector actors to choke off the precursors and finished drugs that drive overdose deaths and violent crime in the United States. It also carries direct implications for the private sector: legal and compliance analysts have noted that the plan's aggressive, coordinated use of sanctions, customs, anti-money-laundering, and criminal authorities raises the enforcement stakes for global businesses whose supply chains or financial dealings could intersect with designated organizations, putting a premium on due diligence.The Strategy's reception has been mixed. Supporters portray it as the most sweeping overhaul of U.S. drug policy in a generation and credit its breadth for bringing prevention, treatment, surveillance, and enforcement under a single framework. Others have questioned whether ambition will be matched by execution — asking how many of its proposals will secure sustained funding, how progress will be measured against the named benchmarks, and whether the heavy emphasis on enforcement will reinforce or instead crowd out the prevention and treatment investments that evidence suggests are essential. Some public-policy analysts have urged a more comprehensive demand-side approach, including continued support for community naloxone distribution and easier access to evidence-based addiction treatment, cautioning that supply reduction works best when paired with robust health interventions. The plan's success, however, will hinge on sustained interagency coordination, international cooperation from the countries named, and the ability of law enforcement and regulatory agencies to actually meet the specific operational targets laid out in the document.